Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation
about
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradationMultilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting stepsAntiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteractionVpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanismHIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomesNMR structural characterization of HIV-1 virus protein U cytoplasmic domain in the presence of dodecylphosphatidylcholine micellesModulation of HIV-1-host interaction: role of the Vpu accessory proteinThe Vpu protein: new concepts in virus release and CD4 down-modulationDirect internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein VpuViral miniproteinsTransmembrane domain determinants of CD4 Downregulation by HIV-1 Vpu.Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.Host restriction factors in retroviral infection: promises in virus-host interaction.Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restrictionβ-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression.Modulation of beta-catenin and E-cadherin interaction by Vpu increases human immunodeficiency virus type 1 particle release.Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4⁺ T cells.Interferon-induced SCYL2 limits release of HIV-1 by triggering PP2A-mediated dephosphorylation of the viral protein Vpu.βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin
P2860
Q21089617-F451B90F-9958-4FC9-B57D-4C6E637F4C6BQ21131559-86957A79-3B2D-4CF6-9610-A784271D6907Q24635271-DF830B08-2D8F-4ECF-9C13-1B595B989314Q24644811-CDF0DA38-5958-421F-A588-8F10F5FDF6D1Q24646984-A9B1A114-98FF-4D78-8E1E-8CDC8A0C3111Q27657668-39B54E98-0425-49A6-BE9C-31AAF039F353Q30397761-9E059E5E-A700-4B72-936E-E871F08B461BQ34021500-854578F4-00CA-405B-B870-1E83A1EEBE4FQ34084429-8A80A14C-A1EB-4775-AAE3-2F5E85092F33Q35151120-EFB55CB5-D669-4829-BE61-C22856A6727BQ35665886-FC05FDD3-1846-4196-A055-B02F08EDE2C4Q35922462-41AA39CB-20F4-4424-9922-4E8965CF3C84Q36376142-32222E05-F5F3-46F5-B959-1D94BA959A16Q36548179-C5859A65-6EB1-4939-AC77-341D3344AA75Q38910738-FF2B2FD4-12E2-4EB2-8F9B-A97E26BDD08EQ39175785-9AD5EB42-66D1-4ACE-8096-F4CA052D5AB8Q39536992-EA347EA9-3F46-4F65-B821-6871781A3AE3Q39594626-17BF4338-8235-4698-BED6-5EDC4B7949A9Q39769799-E96A1C8F-E66C-445E-92EA-F4F55BC63416Q40015792-4286AAD8-CED9-4CAD-AB7B-FF2CF433A019Q42211475-17438E08-3332-4048-A4A6-E1E584A0FDC9Q54478839-B09D68A6-5633-465D-B862-50CA2D9FB5DDQ57811810-6CAF4428-62B7-4E73-905B-9C3173750382
P2860
Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@ast
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@en
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@nl
type
label
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@ast
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@en
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@nl
prefLabel
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@ast
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@en
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@nl
P2093
P2860
P356
P1433
P1476
Silencing of both beta-TrCP1 a ...... u-mediated CD4 down-modulation
@en
P2093
Christophe Butticaz
Josiane Wyniger
Olivier Michielin
Sylvia Rothenberger
P2860
P304
P356
10.1128/JVI.01711-06
P407
P577
2007-02-01T00:00:00Z